USD icon

ProShares Ultra Semiconductors

64.52 USD
+2.84
4.60%
At close Dec 20, 4:00 PM EST
After hours
64.80
+0.28
0.43%
1 day
4.60%
5 days
-3.95%
1 month
-3.27%
3 months
15.46%
6 months
-16.27%
Year to date
153.42%
1 year
153.62%
5 years
731.44%
10 years
3,062.75%
0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

225% more call options, than puts

Call options by funds: $36.1M | Put options by funds: $11.1M

38% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 8

0.21% more ownership

Funds ownership: 4.61% [Q2] → 4.82% (+0.21%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

3% less capital invested

Capital invested by funds: $57.9M [Q2] → $56.4M (-$1.46M) [Q3]

16% less funds holding

Funds holding: 45 [Q2] → 38 (-7) [Q3]

44% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 16

Research analyst outlook

We haven’t received any recent analyst ratings for USD.

Financial journalist opinion

Neutral
Business Wire
3 weeks ago
Worldwide Hardcopy Peripherals Shipments Increased 3.8% Year Over Year in The Third Quarter of 2024, According to IDC
NEEDHAM, Mass.--(BUSINESS WIRE)-- #BROTHER--The global HCP market rebounded in the third quarter of 2024, achieving a 3.8% year-over-year (YoY) growth to approximately 20.3 million units shipped in., This marks a positive shift following five consecutive quarters of YoY declines, according to the IDC Worldwide Quarterly Hardcopy Peripherals Tracker. While the US and PRC experienced YoY declined -2.0% and -8.8%, respectively, all other regional markets reported YoY increases. Growth in these markets was dr.
Worldwide Hardcopy Peripherals Shipments Increased 3.8% Year Over Year in The Third Quarter of 2024, According to IDC
Neutral
Accesswire
1 month ago
Idaho Strategic Reports Third Quarter 2024 Operating and Financial Performance
Highlighted by an 86.39% Increase in Revenue and a 376.44% Increase in Net Income - IDR Continued its Strong Financial Performance Despite Increased Exploration Expense Leading to the Discovery of the Red Star Vein COEUR D'ALENE, ID / ACCESSWIRE / November 4, 2024 / Idaho Strategic Resources, Inc. (NYSE American:IDR) ("IDR", "Idaho Strategic" or the "Company") today announced its consolidated operating and financial results for the second quarter ending September 30, 2024. IDR achieved an 86.39% increase in revenue and a 376.44% increase in net income compared to the second quarter of 2023.
Idaho Strategic Reports Third Quarter 2024 Operating and Financial Performance
Neutral
Business Wire
1 month ago
ProShares Announces ETF Share Splits
BETHESDA, Md.--(BUSINESS WIRE)--ProShares announced forward and reverse share splits on 22 of its ETFs.
ProShares Announces ETF Share Splits
Positive
Zacks Investment Research
2 months ago
5 Best Leveraged ETFs of the First Nine Months of 2024
We highlight a bunch of the best-performing leveraged equity ETFs that have gained more than 70% in the first nine months of 2024.
5 Best Leveraged ETFs of the First Nine Months of 2024
Positive
Seeking Alpha
2 months ago
USD Is Rested And Ready To Go Again
USD, a 2x leveraged ETF, has a 58% concentration in NVDA and 17% in AVGO, making it high risk but with huge potential rewards. After consolidating in Q2 and Q3, USD's valuations are more attractive, and a bullish long-term pattern suggests a potential Q4 rally. The ETF's performance heavily depends on NVDA's earnings and broader semiconductor trends; investors should monitor these closely and consider setting stop losses.
USD Is Rested And Ready To Go Again
Neutral
Accesswire
4 months ago
Idaho Strategic Reports Second Quarter 2024 Operating and Financial Performance
Highlighted by an 89.26% Increase in Revenue and a 558.30% Increase in Net Income - IDR's 6-Month Net Income in 2024 is Nearly 4x Last Year's Total Net Income COEUR D'ALENE, ID / ACCESSWIRE / July 30, 2024 / Idaho Strategic Resources, Inc. (NYSE American:IDR) ("IDR", "Idaho Strategic" or the "Company") today announced its consolidated operating and financial results for the second quarter ending June 30, 2024. IDR achieved an 89.26% increase in revenue and a 558.30% increase in net income compared to the second quarter of 2023.
Idaho Strategic Reports Second Quarter 2024 Operating and Financial Performance
Positive
Seeking Alpha
5 months ago
USD: A Watered-Down Version Of NVDL
Semiconductor industry momentum driven by Nvidia Corporation stock, with market-cap weighted ETFs heavily influenced by the stock's performance. ProShares Ultra Semiconductors ETF offers leveraged exposure to the semiconductor industry, but heavily weighted towards Nvidia. Consider using GraniteShares 2x Long NVDA Daily ETF for a more pure play on Nvidia, with potentially higher returns but also higher risk.
USD: A Watered-Down Version Of NVDL
Positive
Zacks Investment Research
5 months ago
5 Best-Performing Leveraged ETFs of 1H
We highlight a bunch of the best-performing leveraged equity ETFs from different corners of the market that are leaders in their segments for the first half.
5 Best-Performing Leveraged ETFs of 1H
Positive
Zacks Investment Research
5 months ago
5 Best Leveraged ETFs of the Second Quarter of 2024
The second quarter proved to be a banner quarter for Wall Street, with the S&P 500 and the Nasdaq Composite Index scaling new record highs on several occasions.
5 Best Leveraged ETFs of the Second Quarter of 2024
Neutral
Accesswire
6 months ago
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
TORONTO, ON / ACCESSWIRE / June 20, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that in preclinical research, it's lead drug formulation, Rutherrin® was able to repurpose non-cancer drugs for cancer therapy. Drug repurposing is the process of finding new uses for existing clinically approved drugs.
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
Charts implemented using Lightweight Charts™